CN1206213C - N-芳基磺酰氨基酸ω-酰胺 - Google Patents
N-芳基磺酰氨基酸ω-酰胺 Download PDFInfo
- Publication number
- CN1206213C CN1206213C CNB998129321A CN99812932A CN1206213C CN 1206213 C CN1206213 C CN 1206213C CN B998129321 A CNB998129321 A CN B998129321A CN 99812932 A CN99812932 A CN 99812932A CN 1206213 C CN1206213 C CN 1206213C
- Authority
- CN
- China
- Prior art keywords
- alkyl
- formula
- hydrogen atom
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19851184A DE19851184A1 (de) | 1998-11-06 | 1998-11-06 | N-Arylsulfonyl-aminosäure-omega-amide |
| DE19851184.1 | 1998-11-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1332724A CN1332724A (zh) | 2002-01-23 |
| CN1206213C true CN1206213C (zh) | 2005-06-15 |
Family
ID=7886902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB998129321A Expired - Fee Related CN1206213C (zh) | 1998-11-06 | 1999-10-21 | N-芳基磺酰氨基酸ω-酰胺 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US6201130B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1124797B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4348014B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR100655632B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1206213C (cg-RX-API-DMAC7.html) |
| AR (1) | AR021086A1 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE260889T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU757602B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR9915729A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2350031C (cg-RX-API-DMAC7.html) |
| CZ (1) | CZ302291B6 (cg-RX-API-DMAC7.html) |
| DE (2) | DE19851184A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1124797T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2213405T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1041686B (cg-RX-API-DMAC7.html) |
| HU (1) | HUP0104122A3 (cg-RX-API-DMAC7.html) |
| ID (1) | ID28810A (cg-RX-API-DMAC7.html) |
| PL (1) | PL198827B1 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1124797E (cg-RX-API-DMAC7.html) |
| RU (1) | RU2228330C2 (cg-RX-API-DMAC7.html) |
| TR (1) | TR200101245T2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2000027808A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200103485B (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003042190A1 (en) | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
| PA8557501A1 (es) | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
| US7071223B1 (en) * | 2002-12-31 | 2006-07-04 | Pfizer, Inc. | Benzamide inhibitors of the P2X7 receptor |
| PA8591801A1 (es) | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | Inhibidores benzamidicos del receptor p2x7. |
| MXPA05010165A (es) * | 2003-04-15 | 2005-11-16 | Warner Lambert Co | Derivados de prolina biciclicos [c]-condensados y su uso para el tratamiento de estados artriticos. |
| EP1626962B1 (en) * | 2003-05-12 | 2007-02-28 | Pfizer Products Inc. | Benzamide inhibitors of the p2x7 receptor |
| CN1980902A (zh) * | 2004-06-29 | 2007-06-13 | 辉瑞产品有限公司 | 通过对羟基保护前体去保护而制备5-4-(2-羟基-丙基)-3,5-二氧代-4,5-二氢-3h-[1,2,4]三嗪-2-基-苯甲酰胺衍生物的方法 |
| CA2572118A1 (en) * | 2004-06-29 | 2006-01-12 | Pfizer Products Inc. | Method for preparing 5-`4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3h-`1,2,4!-triazin-2-yl!benzamide derivatives with p2x7 inhibiting activity by reaction of the derivative unsubstituted in 4-position of the triazine with an oxiran in the presence of a lewis acid |
| BRPI0512915A (pt) * | 2004-06-29 | 2008-04-15 | Warner Lambert Co | terapias de combinação utilizando inibidores benzamida do receptor p2x7 |
| US7576222B2 (en) | 2004-12-28 | 2009-08-18 | Wyeth | Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase |
| MY144590A (en) | 2005-07-11 | 2011-10-14 | Wyeth Corp | Glutamate aggrecanase inhibitors |
| KR20080058436A (ko) | 2005-10-13 | 2008-06-25 | 와이어쓰 | 글루탐산 유도체의 제조 방법 |
| WO2012004743A1 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
| EP2953932B1 (en) * | 2013-02-06 | 2017-03-01 | Merck Patent GmbH | Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1063026A1 (ru) * | 1982-05-19 | 1990-12-07 | Институт биохимии АН ЛитССР | N @ -Бензолсульфонильные производные трес-DL-фенилсерина, обладающие противовоспалительной активностью |
| JP2764262B2 (ja) | 1987-08-28 | 1998-06-11 | 持田製薬株式会社 | ヒダントイン誘導体及びそれを有効成分とする医薬組成物 |
| TW201303B (cg-RX-API-DMAC7.html) | 1990-07-05 | 1993-03-01 | Hoffmann La Roche | |
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| AU690703B2 (en) | 1994-06-22 | 1998-04-30 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
| US5863949A (en) * | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| EP0837901A1 (en) * | 1995-06-28 | 1998-04-29 | E.I. Du Pont De Nemours And Company | Fluoropolymer nanocomposites |
| KR980009238A (ko) | 1995-07-28 | 1998-04-30 | 우에노 도시오 | 설포닐아미노산 유도체 |
| CZ294063B6 (cs) * | 1996-05-17 | 2004-09-15 | Warner-Lambert Company | Bifenylsulfonamid, jeho použití a farmaceutický prostředek s jeho obsahem |
| DE19719621A1 (de) * | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
-
1998
- 1998-11-06 DE DE19851184A patent/DE19851184A1/de not_active Withdrawn
-
1999
- 1999-10-21 AT AT99971799T patent/ATE260889T1/de active
- 1999-10-21 DK DK99971799T patent/DK1124797T3/da active
- 1999-10-21 CN CNB998129321A patent/CN1206213C/zh not_active Expired - Fee Related
- 1999-10-21 ID IDW00200100995A patent/ID28810A/id unknown
- 1999-10-21 RU RU2001115706/04A patent/RU2228330C2/ru not_active IP Right Cessation
- 1999-10-21 CA CA2350031A patent/CA2350031C/en not_active Expired - Fee Related
- 1999-10-21 PT PT99971799T patent/PT1124797E/pt unknown
- 1999-10-21 JP JP2000580988A patent/JP4348014B2/ja not_active Expired - Fee Related
- 1999-10-21 HU HU0104122A patent/HUP0104122A3/hu unknown
- 1999-10-21 HK HK02103391.7A patent/HK1041686B/zh not_active IP Right Cessation
- 1999-10-21 DE DE59908769T patent/DE59908769D1/de not_active Expired - Lifetime
- 1999-10-21 WO PCT/EP1999/007979 patent/WO2000027808A1/de not_active Ceased
- 1999-10-21 ES ES99971799T patent/ES2213405T3/es not_active Expired - Lifetime
- 1999-10-21 TR TR2001/01245T patent/TR200101245T2/xx unknown
- 1999-10-21 EP EP99971799A patent/EP1124797B1/de not_active Expired - Lifetime
- 1999-10-21 BR BR9915729-2A patent/BR9915729A/pt not_active Application Discontinuation
- 1999-10-21 CZ CZ20011506A patent/CZ302291B6/cs not_active IP Right Cessation
- 1999-10-21 KR KR1020017005590A patent/KR100655632B1/ko not_active Expired - Fee Related
- 1999-10-21 PL PL347574A patent/PL198827B1/pl not_active IP Right Cessation
- 1999-10-21 AU AU11530/00A patent/AU757602B2/en not_active Ceased
- 1999-11-04 AR ARP990105584A patent/AR021086A1/es active IP Right Grant
- 1999-11-05 US US09/434,107 patent/US6201130B1/en not_active Expired - Lifetime
-
2000
- 2000-12-28 US US09/749,034 patent/US6335333B1/en not_active Expired - Lifetime
-
2001
- 2001-04-30 ZA ZA200103485A patent/ZA200103485B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU757602B2 (en) | 2003-02-27 |
| DK1124797T3 (da) | 2004-07-05 |
| ES2213405T3 (es) | 2004-08-16 |
| HK1041686B (zh) | 2005-09-23 |
| EP1124797A1 (de) | 2001-08-22 |
| ZA200103485B (en) | 2001-12-04 |
| JP2002529447A (ja) | 2002-09-10 |
| DE59908769D1 (de) | 2004-04-08 |
| CA2350031C (en) | 2010-01-26 |
| AU1153000A (en) | 2000-05-29 |
| KR100655632B1 (ko) | 2006-12-12 |
| JP4348014B2 (ja) | 2009-10-21 |
| HUP0104122A3 (en) | 2002-04-29 |
| RU2228330C2 (ru) | 2004-05-10 |
| PL347574A1 (en) | 2002-04-08 |
| KR20010080385A (ko) | 2001-08-22 |
| PL198827B1 (pl) | 2008-07-31 |
| CZ302291B6 (cs) | 2011-02-09 |
| US6335333B1 (en) | 2002-01-01 |
| US6201130B1 (en) | 2001-03-13 |
| AR021086A1 (es) | 2002-06-12 |
| TR200101245T2 (tr) | 2001-10-22 |
| DE19851184A1 (de) | 2000-05-11 |
| EP1124797B1 (de) | 2004-03-03 |
| CN1332724A (zh) | 2002-01-23 |
| HK1041686A1 (en) | 2002-07-19 |
| BR9915729A (pt) | 2001-10-23 |
| ID28810A (id) | 2001-07-05 |
| HUP0104122A2 (hu) | 2002-03-28 |
| CA2350031A1 (en) | 2000-05-18 |
| WO2000027808A1 (de) | 2000-05-18 |
| CZ20011506A3 (cs) | 2001-08-15 |
| PT1124797E (pt) | 2004-07-30 |
| ATE260889T1 (de) | 2004-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1280267C (zh) | 磺酰氨基羧酸 | |
| CN1207056C (zh) | 含肽的α-酮酰胺半胱氨酸和丝氨酸蛋白酶抑制剂 | |
| CN1149210C (zh) | 凝血酶抑制剂 | |
| CN1134264C (zh) | 抗血栓形成剂 | |
| CN1023700C (zh) | 芳族及杂环甲酰胺衍生物抗肿瘤剂的制备 | |
| CN1165815A (zh) | 酚化合物及其制备方法 | |
| CN1688548A (zh) | 喹啉抗生素中间体的制备方法 | |
| CN1228780A (zh) | 用作基质金属蛋白酶抑制剂的次膦酸酰胺 | |
| CN1198096A (zh) | 用于治疗与胶原蛋白过量产生有关的疾病的c-蛋白酶抑制剂 | |
| CN1520293A (zh) | 作为抗糖尿病药物的3-氟-吡咯烷类 | |
| CN1377268A (zh) | 细胞粘合抑制剂 | |
| CN1072667C (zh) | 含咪唑取代基的巯基烷基肽基化合物及其用作基质金属蛋白酶(mmp)和/或肿瘤坏死因子(tnf)抑制剂 | |
| CN1040211C (zh) | 基质金属蛋白酶抑制剂 | |
| CN1131144A (zh) | 甘氨酰胺衍生物及其制法和含有它们的药物 | |
| CN1066150C (zh) | 作为基质金属蛋白酶抑制剂的桥式吲哚 | |
| HK1041686A1 (en) | N-arylsulfonyl amino acid omega amedes | |
| HK1042691A1 (zh) | 磺酰胺异羟肟酸脂 | |
| CN1729173A (zh) | N-(吲哚乙基)环胺化合物 | |
| CN1127488C (zh) | 具有生长激素释放特性的化合物 | |
| CN1038103A (zh) | 环烷基取代的戊二酰胺利尿剂和其制备方法 | |
| CN1291197A (zh) | 新的乙酰胺衍生物及其用途 | |
| CN1212835C (zh) | 含异羟肟酸酯的半胱氨酸和丝氨酸蛋白酶抑制剂 | |
| CN1425004A (zh) | 含杂环侧链的n-取代的金属蛋白酶抑制剂 | |
| CN1418210A (zh) | 含有碳环侧链的n-取代金属蛋白酶抑制剂 | |
| CN1208333C (zh) | 主要用于治疗骨质疏松的吲哚衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| C10 | Entry into substantive examination | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: SANOFI- AVENTIS GERMAN CO., LTD. Free format text: FORMER NAME OR ADDRESS: AVENTIS PHARMACY (GERMANY)INTERNATIONAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: Frankfurt, Germany Patentee after: AVENTIS PHARMA DEUTSCHLAND GmbH Address before: Frankfurt, Germany Patentee before: AVENTIS PHARMA DEUTSCHLAND GmbH |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050615 Termination date: 20111021 |